{"entity":{"id":"nct05377996","kind":"trial","name":"A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of Emi-Le in triple-negative breast cancer, endometrial cancer, ovarian cancer and salivary gland cancers, run by Day One Biopharmaceuticals, Inc., now recruiting.","summary":"A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors is a phase 1/2 interventional study registered as NCT05377996 by Day One Biopharmaceuticals, Inc., with 360 participants planned, started 2022-08-15 and due to reach its primary completion in 2027-02. Interventions recorded: Emi-Le.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05377996","url":"https://clinicaltrials.gov/study/NCT05377996"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["tnbc","endometrial","ovarian","salivary-gland"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["day-one-biopharmaceuticals"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05377996","phase":"1/2","setting":"A Phase 1/2, First-in-human, Multicenter Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors","sponsor":"Day One Biopharmaceuticals, Inc.","enrolled":360,"outcomes":[]},"route":"/trials/nct05377996/","neighbours":{"cancer":[{"id":"endometrial","kind":"cancer","name":"Endometrial cancer","route":"/cancers/endometrial/"},{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"},{"id":"salivary-gland","kind":"cancer","name":"Salivary gland cancers","route":"/cancers/salivary-gland/"},{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/"}],"company":[{"id":"day-one-biopharmaceuticals","kind":"company","name":"Day One Biopharmaceuticals","route":"/companies/day-one-biopharmaceuticals/"}]}}